Insiders Trades
Otofarma Stock: price and insider trades · Italy
Otofarma: what insiders have been doing
This page follows insider dealings at Otofarma as filed with Consob, a company from the Health Care sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Otofarma logged 2 filings by 2 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Insider buying of Otofarma has been absent for the past year.
Across the 224 companies tracked on its exchange, the median is 3 filings; at 2 filings, this issuer sits below that mark.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Source: insider filings from Consob. Past trades are no guide to future returns.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 1,958 of 24,148 companies
75.6
score / 100
Value75
Quality76
FCF yld14%
Earn yld4.9%
EV/EBITDA7.4x
ROE57%
Gross mgn89%
Net mgn4.6%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended December 2024 · cache
€2.40
Analyst consensus
1 analysts€5.40Target €5.40(+125%)€5.40
Income statement
Revenue€15.2M
Gross profit€13.5M89% margin
EBITDA€2.3M15% margin
Net income€698k14.6% margin
Valuation
PER (trailing)20.0x
PER (forward)17.1x
Balance sheet & cash
Market cap€14.3M
Total debt€2.9M
Free Cash Flow€2.0M
Profitability & ownership
ROE56.9%
ROA25.8%
% insiders89.3%
% institutions1.6%
Last declaration on 28 May 2026
About Otofarma
Otofarma is a company operating in the health and pharmaceutical sector, specializing in the development of pharmaceutical solutions. It is listed on the XMIL market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
